Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Current & emerging biomarkers in multiple myeloma

Noemí Puig • 26 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, outlines current and emerging biomarkers used at diagnosis in multiple myeloma, highlighting the potential of circulating tumor plasma cells as a prognostic factor in both smoldering myeloma and multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Noemí Puig

1:02
Challenges associated with developing a standardized technique for MRD detection in myeloma
Noemí Puig • 29 Sep 2023
2:37
Evidence supporting MRD-guided treatment breaks in MM
Noemí Puig • 29 Sep 2023
1:20
Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM
Noemí Puig • 29 Sep 2023
4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals